REVEAL 2.0 Clinical Assessment
Validated for WHO Group 1 PAH. Goal-directed therapy targets a Low Risk (≤6) status.
Etiology & History
REVEAL Lite Zone
Clinical & Functional
0
0
Invasive & Diagnostics
DLCO % Predicted
0
Mean RAP (mmHg)
0
PVR (Wood units)
0
Ready for Assessment
Guidelines & Evidence
Verified
Last Review: 2026
Last Comprehensive Review: 2026
